Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

The European Association for the Study of Obesity (EASO) has recommended Novo Nordisk's semaglutide (Wegovy/Ozempic) and Eli Lilly's tirzepatide (Zepbound/Mounjaro) as first-line treatments for obesity and its complications, citing their superior efficacy for substantial weight loss. The new guidelines, published in Nature Medicine, specify these GLP-1 drugs for various obesity-related conditions, including obstructive sleep apnea, heart disease, and non-alcoholic fatty liver disease. This endorsement underscores the transformative impact of these blockbuster medications on obesity care and signals significant market expansion and continued dominance for their manufacturers, despite acknowledged high costs.

Analysis

A new non-binding guideline from the European Association for the Study of Obesity (EASO), published in Nature Medicine, strongly endorses Novo Nordisk's semaglutide and Eli Lilly's tirzepatide as first-line treatments for obesity, a significant tailwind for both companies. The guidance positions these GLP-1 agonists as the primary choice for patients requiring substantial weight loss, effectively solidifying their market dominance over older, less effective medications. The analysis provides specific therapeutic pathways, recommending tirzepatide for conditions like obstructive sleep apnea and non-alcoholic fatty liver disease, and semaglutide for knee osteoarthritis and patients with a history of heart disease. While acknowledging the drugs' high costs, the guideline authors argue that the expense of not treating obesity and its complications should be a key consideration in health policy, potentially aiding future reimbursement negotiations. Despite the bullish endorsement, the report also incorporates cautionary notes from U.S. medical societies regarding challenges such as gastrointestinal side effects, high costs, and weight regain upon discontinuation, which remain key variables for long-term market penetration and patient adherence.

Key Decisions for Investors

• This strong endorsement from a major European medical body reinforces the long-term revenue and market leadership thesis for Novo Nordisk and Eli Lilly, supporting a continued bullish stance on their obesity drug franchises.
• Investors should monitor developments in healthcare policy and reimbursement, as the guideline's argument about the cost of untreated obesity could influence coverage decisions and mitigate pricing pressure.
• Key risks to track include patient discontinuation rates due to side effects and the potential for market access limitations tied to high costs, as these factors could temper the otherwise robust growth outlook.
• Monitor future clinical data for expanded indications mentioned in the article, such as chronic kidney disease and neurodegenerative disorders, as these represent significant upside catalysts for the total addressable market.